The October 2026 CPI report, released November 10, showed headline inflation rose 0.4% month-over-month — above the 0.3% consensus and the third straight month of 0.4%+ gains. Core CPI rose 0.3%, also above the 0.2% forecast and the third consecutive month at that level. The BLS did not publish year-over-year figures because the October 2025 government shutdown prevented data collection, leaving no comparison base. Economists estimate annual headline inflation at roughly 4.1% and core at 2.8%.
The surprise was driven by food inflation accelerating from 0% to 0.5% monthly, transportation services up 0.8% (highest since January), recreation services up 0.9%, and motor vehicle insurance up 0.7% — a full percentage point above Goldman's forecast. Used car prices fell 1.2%, but that was offset by new car prices rising 0.3%. The report landed at a critical moment for the Fed, with traders now fully pricing a quarter-point December hike and putting 13.6% odds on a half-point move, up from near zero before the release.
The post lists Goldman Sachs and Morgan Stanley at 0.1% for October core CPI m/m, but their published forecasts were 0.16% and 0.19% respectively — both round to 0.2%, not 0.1%. Actual October core CPI came in at 0.3%, hotter than all listed estimates.
A group of banks including Goldman Sachs, Citigroup, Santander and Deutsche Bank committed roughly $270 million to Project Faro, a joint stablecoin venture, according to Bloomberg.
Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on November 2, 2026, and announced a proposed merger with Ayrmid Ltd.
Same as post 2120126073518121407 — Goldman and Morgan Stanley's actual core CPI forecasts were 0.16% and 0.19%, not 0.1%.
FuturHealth, a San Diego-based direct-to-consumer GLP-1 platform, filed for Chapter 11 on November 1, 2026, citing an underperforming ~$13.5M iHeartMedia ad deal among the causes.
Fed Governor Austan Goolsbee called the October CPI report "borderline disturbing" as the cen
AThe banks are building their own stablecoin, and they're putting real money behind it.
BTwo hundred seventy million dollars. For a bunch of banks, that's lunch money.
AIt's not the size, it's the signal. Goldman, Citi, Santander, Deutsche Bank — they're not doing this as a hobby.
BProject Faro. Bloomberg says they've committed the money to a joint stablecoin venture.
AAnd that's the part I find interesting. These are the same institutions that spent years calling crypto a scam.
BNow they want their own version. Funny how that works.
AThe difference is, this one's backed by actual banks with actual balance sheets. Not a guy in a hoodie.
BThat's the pitch. But let's be honest — a bank stablecoin is just a faster way to move dollars.
AWhich is exactly what corporate treasuries want. Settlement in seconds, not days.
BI'll give them this: if anyone can make a stablecoin boring enough to work, it's Goldman Sachs.
AThat's the most backhanded compliment I've heard all week.
BSpeaking of banks and bad news — Karyopharm Therapeutics just filed for Chapter 11.
AThe cancer drug company. Filed November second, and they've already got a merger lined up with Ayrmid.
BThat's the playbook now. File, restructure, merge, come out the other side.
AIt's not a liquidation. It's a reorganization with a dance partner already picked.
BAnd that's the part retail investors always miss. Chapter 11 doesn't mean the company's dead.
AIt means the old shareholders usually get wiped out, and the new owners get the assets.
BExactly. The name might survive, but the people who held the stock? Different story.
ADifferent world entirely: Alibaba is spinning off its chip business.
BT-Head. Their Nvidia competitor. They filed confidentially back in September for a Hong Kong listing.
ACNBC is reporting it. Alibaba wants to list the chip unit on the Hong Kong exchange.
BThis is the part of the China story nobody talks about enough. They're not just buying chips, they're building them.
AAnd now they're going to let public markets fund it. Smart move, honestly.
BIt's a signal. They think T-Head is ready to stand on its own.
AOr they need the cash. Alibaba's been under pressure, and a listing raises real money.
BBoth can be true. That's usually how these things work.
BOne more story before we go. A direct-to-consumer GLP-1 platform just went under.
AFuturHealth, out of San Diego. Filed Chapter 11 on November first.
BAnd the reason is wild. They had a thirteen and a half million dollar ad deal with iHeartMedia that underperformed.
ASo a weight-loss drug company spent millions on radio ads, and it didn't work.
BThe post says iHeartMedia itself is now one of the creditors. That's a mess.
AIt's a cautionary tale. You can't just buy customers with ads and hope the math works out.
BEspecially in GLP-1s. The big pharma companies are eating everyone's lunch.
AAnd the acquisition cost for these patients is brutal. You spend a fortune to get one customer.
BThen they churn. It's a terrible business model if you don't have deep pockets.
AThat's the show for now. We'll be back with more after the break.